SCHEMBL4081845

SCHEMBL4081845

O=Cc1ccccc1NC(=O)c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SNCA P37840 5/20 0.59
MDM4 O15151 1/20 0.58
TP53 P04637 1/20 0.58
HDAC3 O15379 1/20 0.58
MAPK1 P28482 1/20 0.58
HDAC1 Q13547 1/20 0.58
HDAC2 Q92769 1/20 0.58
POLB P06746 1/20 0.58
HPGD P15428 1/20 0.58
NPC1 O15118 3/20 0.56
RAB9A P51151 3/20 0.56
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2D6 P10635 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
KMT2A Q03164 5/20 0.51
MEN1 O00255 4/20 0.51
MAPT P10636 4/20 0.51
TDP1 Q9NUW8 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30758797 1.00 SNCA (0.59) SNCAMDM4TP53HDAC3MAPK1
SCHEMBL14289944 0.88 MEN1 (0.50) SNCAMDM4TP53HDAC3MAPK1
SCHEMBL8277234 0.85 NPC1 (0.56) SNCAMDM4TP53HDAC3MAPK1
SCHEMBL7707926 0.84 MEN1 (0.53) MAPK1POLBNPC1RAB9ACYP1A2
SCHEMBL27664630 0.84 SNCA (0.57) SNCAMDM4TP53HDAC3MAPK1
SCHEMBL29954708 0.83 SNCA (0.61) SNCAMDM4TP53HDAC3MAPK1
SCHEMBL11319558 0.82 F10 (0.74) SNCATP53HDAC3HDAC1HDAC2
SCHEMBL13838766 0.82 NPC1 (0.55) HDAC3HDAC1HDAC2HPGDNPC1
SCHEMBL13888851 0.82 SMN1; SMN2 (0.58) SNCAHDAC3MAPK1HDAC1HDAC2
SCHEMBL6694722 0.82 LMNA (0.48) SNCAPOLBHPGDNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117550997-A LAT1 inhibitor and preparation method and application thereof 中国药科大学 2024-02-13 CN disclosed
CN-117466761-A Glutamine transport inhibitor, pharmaceutical composition and application 中国药科大学 2024-01-30 CN disclosed
CN-110218137-B Synthetic method of anthranilic aldehyde compound 上海交通大学 2021-01-22 CN disclosed
JP-2009107972-A AMINOBENZALDEHYDE COMPOUND, METHOD FOR PRODUCING THE SAME, AND METHOD FOR PRODUCING AMINOBENZOIC ACID COMPOUND FUJI CHEM IND CO LTD 2009-05-21 JP disclosed
JP-2009106923-A CATALYTIC HYDROGENATION METHOD AND NOVEL CATALYST THEREFORE EMMELLEN BIOTECH PHARMACEUTICALS LTD 2009-05-21 JP disclosed
EP-1845083-A2 New arylsulfonohydrazide inhibitors of enzymes MurC and MurD UNIVERZA V LJUBLJANI, FAKULTETA ZA FARMACIJO (SI) 2007-10-17 EP disclosed
US-20060058366-A1 Jnk inhibitor KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-03-16 US disclosed
EP-1582211-A1 JNK INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2005-10-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058366-A1 Jnk inhibitor MAPK3, MAPK4, MAPKAPK3 SNCA 4594/4885MDM4 2033/4885TP53 2856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.